Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 8.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 878,998 shares of the company's stock after selling 83,229 shares during the period. Dimensional Fund Advisors LP owned approximately 1.47% of Twist Bioscience worth $40,850,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TWST. Arizona State Retirement System raised its holdings in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock valued at $789,000 after buying an additional 219 shares during the period. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. lifted its position in shares of Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after purchasing an additional 300 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after purchasing an additional 443 shares during the period. Finally, US Bancorp DE lifted its holdings in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TWST shares. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. The Goldman Sachs Group lowered their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday. Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Robert W. Baird lowered their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. decreased their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 689 shares of the company's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the sale, the insider now owns 110,849 shares in the company, valued at approximately $4,173,464.85. This represents a 0.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Paula Green sold 918 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,991 shares of company stock worth $742,654. 3.01% of the stock is owned by insiders.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded down $1.22 on Friday, reaching $31.39. 323,157 shares of the company were exchanged, compared to its average volume of 965,179. The company has a 50-day moving average of $38.81 and a 200-day moving average of $43.74. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -9.29 and a beta of 2.54. Twist Bioscience Co. has a 1-year low of $31.03 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.